Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).
about
An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesNew ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromeRecent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemiaInterferon regulatory factor-8 is important for histone deacetylase inhibitor-mediated antitumor activity.Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience.Successful treatment with low-dose decitabine in acute myelogenous leukemia in elderly patients over 80 years old: Five case reportsA phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.Epigenetic therapies in MDS and AML5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature.Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and MarrowAn International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.Chronic myelomonocytic leukemia: Forefront of the field in 2015.Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trialFighting back against chronic myelomonocytic leukemia.5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome--a systematic review and meta-analysis.Current status of allogeneic HST for chronic myelomonocytic leukemia.Heterogeneity of molecular markers in chronic myelomonocytic leukemia: a disease associated with several gene alterations.Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groupsChronic myelomonocytic leukemia prognostic classification and management: evidence base and current practice.I walk the other line: myelodysplastic/myeloproliferative neoplasm overlap syndromes.Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update.Acute myeloid leukemia arising from chronic myelomonocytic leukemia during hypomethylating therapy.Inhibition studies of DNA methyltransferases by maleimide derivatives of RG108 as non-nucleoside inhibitors.Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management.Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.Treatment of chronic myelomonocytic leukemia with 5-azacytidine: case reports.Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy.Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire.Therapy for Chronic Myelomonocytic Leukemia in a New Era.Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib.Myelodysplastic/myeloproliferative neoplasms: a disease in need of recognition.Activity of azacitidine in chronic myelomonocytic leukemia.Targeting the epigenome for treatment of cancer.Guidelines for the diagnosis and management of adult myelodysplastic syndromes.Outcome of patient with high-risk chronic myelomonocytic leukemia, treated with decitabine prior to transformation to acute myeloid leukemia: A case report.
P2860
Q24622700-8F01C5A2-849B-4B64-9B19-8729CBF9303FQ26829132-BE71D9F3-BEF2-44EA-8793-0F6B018E869AQ28307278-23B4F6BB-E0AC-4A6B-98DE-A1A536FC0C92Q31101656-5CEBC229-9654-46F1-B9A7-094A0646982FQ33392205-27C67783-69FD-4A5A-B634-31A94185D756Q33407141-0A304CE3-6A23-46FE-BB80-0DDE9CFB2AA3Q33442672-A1DB769F-D9B3-4BB5-AA7A-E12F91FAEECDQ33863567-C2710244-F4FE-45EF-B0E3-4276AC80DBA5Q35010676-83A6369F-4C92-45E4-B0DE-A0398126646FQ35714782-7B2ED6FA-3138-49EA-8C40-1187F462BC46Q36708989-38B8CF59-DA6B-4DFB-BDCF-80E8787BA135Q36876853-D46DB52A-3007-4998-BAC1-E140CD5406D9Q36934269-D697C620-A40F-4255-940A-25691CDC1554Q37205575-7C382582-DAB8-4E8A-9B1F-FF83F026E717Q37601778-4BF5747A-76F6-4869-84C7-2F231B8AC12AQ37899751-ED36055A-CF0D-4A62-809F-8A641E9E1300Q37993420-2B289085-73DF-4FD8-83E6-0E83F1E524E9Q38012085-2C39E035-422C-4C77-A3DD-8DF4DE860937Q38130476-139D602E-0AFE-45BD-BA38-DF1809D471FAQ38134374-61B59F3E-8194-4F1D-88C3-91B8FE5CD734Q38241774-465F6ECB-DDC0-4BE7-A86B-B1602A999361Q38246598-10222210-7D23-43BA-9431-544C3EDED3F8Q38540013-3977A5CF-9770-4DE6-8914-A3620A334A75Q38608434-FAEAA1CA-C2CA-412A-9F32-BF8544DD9940Q38644511-D9BA7032-C309-4E7A-BA25-FC42E3E30CACQ38835771-778532A3-723D-4BFF-A830-FD5ABBE6D0BCQ38859646-82C1A93C-A5E5-4017-B8F3-2B32724F3A68Q39560322-CBDD4898-E4B5-4C65-B40A-D1EE10542DCCQ40157327-D91DCB40-20F0-4576-8094-723B712C1047Q41070362-33B2DDCD-7E04-4960-AE8F-FB3571781A37Q42720284-CA1E7A80-1DB5-4DE5-A7C4-85DDDDB73F80Q43247519-7B6AFC6E-736D-4FF7-BA2D-21BF68AB70DFQ46373480-E551BD59-2D96-4DE9-B9D1-124CC0EF72CAQ47853133-8E71DF7A-FC4C-4254-8DA2-4CFA476060A0Q49311338-93ACB66B-02D2-4BC3-9004-D1A7304E90BFQ50891297-07FEFFCF-E5F6-42BE-A72D-298C1E6CE282Q53152113-E1AC9ED6-C1BA-4BC5-914D-D1E30312335DQ53201323-88BE0BC3-ED21-4334-B548-01C1675C8E93Q54392826-3685E6E1-227A-454C-8882-4536485A3CB5Q54979651-9522BDEA-CF1C-4016-938C-EC263E3E91A8
P2860
Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Efficacy of decitabine in the ...... yelomonocytic leukemia (CMML).
@en
type
label
Efficacy of decitabine in the ...... yelomonocytic leukemia (CMML).
@en
prefLabel
Efficacy of decitabine in the ...... yelomonocytic leukemia (CMML).
@en
P2093
P1433
P1476
Efficacy of decitabine in the ...... yelomonocytic leukemia (CMML).
@en
P2093
P304
P356
10.1016/J.LEUKRES.2007.08.004
P577
2007-09-18T00:00:00Z